Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine use beyond 24 horse Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KASCH-NGHA | KAIMRC | Ongoing | Dexmedetomidine | 3 | RC20/160/R | King Abdulaziz Medical City NG (Riyadh) |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises | Global Blood Therapeutics, Inc. | Ongoing | Inclacumab | 3 | GBT2104-131 | Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia , Qatif Central Hospital |
| The Efficacy of topical Povidone – Iodine rinses in the management of CoronaVirus disease 2019 (COVID-19) | PI initiated (KSU) | Ongoing | POVIDONE IODINE | 2 | E-20-5656 | King Khalid University Hospital (Riyadh) |
| Efficacy Of Single Dose Rituximab and Mycophenolate Versus Two Doses Rituximab in Children with Steroid Dependent and Frequent Relapsing Nephrotic Syndrome: Randomized Open-Labeled Pilot Trial | King Faisal Specialist Hospital and Research Center | Ongoing | Rituximab / Mycophenolate | 2 | 2020-99 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Prospective Phase II study utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients with Advanced Colorectal Cancer | KAIMRC | Ongoing | PANITUMUMAB - cetuximab | 2 | RC20/170/R | King Abdulaziz Medical City NG (Riyadh) |
| Deferoxamine management protocol in COVID-19 patients | King Saud Medical City | Ongoing | Deferoxamine | 2 | 20082103 | King Saud Medical City (Riyadh) |
| A global multicenter，randomized，double-blind，placebo -controlled， adaptive designed phase Ⅲ clinical trial to evaluate the efficacy， safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above | MOH / CanSino | Rejected | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | 3 | CS-CTP-AD5NCOV-ⅢCo | King Fahad Medical City (Riyadh) |
| A phase III randomized clinical trial comparing post-transplant cyclophosphamide with calcineurin inhibitors as a GVHD prophylaxis to standard care of methotrexate and calcineurin inhibitors for acute leukemia incorporating patient pharmacogenomic profiling – a personalized medicine approach in allogeneic hematopoietic cell transplantation PMAT | King Faisal Specialist Hospital and Research Centre | Ongoing | CYCLOPHOSPHAMIDE (ENDOXAN) | 3 | 1- 28/05/2019 | KFSH & RC-R |
| Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS) | Eagle Pharmaceuticals | Ongoing | Dantrolene | 2 | EGL-4104-C-1801 | Mina Al-Shari' Al-Jadid Hospital |
| An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | Astellas | Rejected | Mirabegron | 3 | 178-CL-206A | King Abdulaziz University Hospital (Jeddah) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.